Efficacy and safety of apatinib combined with radiotherapy in the treatment of advanced pancreatic cancer: a meta-analysis

Table 1 Basic characteristics of included studies

Study	Year	Classification	Stage	Number	Age(years)		Intervention study		Period	Outcome measures
Study	Year	Classification	Stage	T/C	T	C	T	C	T/C	Outcome measures
Chengming Wei [8]	2019	PC	IV	31/31	44.67 土 4.32	44.82土 4.41	Apatinib (500 mg, qd) + SBRT	SBRT	6 weeks	①②③④⑤⑥⑦⑧⑨⑩⑪⑫⑬⑮⑯
Jue Wang [9]	2021	PC	IV	30/30	57.20 土 5.04	56.61土 4.32	Apatinib (500 mg, qd) + IMRT	IMRT	4 weeks	①②③④⑤⑥⑪⑫⑬⑭⑰
Linjia Wang [10]	2020	PC	IV	33/32	56.61 ± 4.97	57.03 ± 5.05	Apatinib (500 mg, qd) + SBRT	SBRT	6 weeks	①②③④⑤⑥⑪⑫⑬⑮⑯
Pengpeng Xu [11]	2021	PC	IV	31/30	44.36 ± 4.14	44.67 ± 4.78	Apatinib (500 mg, qd) + SBRT	SBRT	6 weeks	①②③④⑤⑥⑪⑫⑬⑯
Yinghui Deng [12]	2022	PC	IV	30/30	59.50 ± 14.5	59.00 ± 16.00	Apatinib (250 mg, qd) + Palliative radiotherapy	Palliative radiotherapy	4 weeks	①②③④⑤⑥⑦⑧⑬⑭⑮⑰
Zhaowei An [13]	2020	PC	IV	30/30	57.31 ± 7.14	54.81 ± 5.82	Apatinib (500 mg, qd) + 3DCRT	3DCRT	4 weeks	①②③④⑤⑥⑨⑩⑬⑯
Zhidong Xue [14]	2020	PC	IV	30/30	58.35 ± 5.38	59.21 ± 5.42	Apatinib (250 mg-500 mg, qd) + Palliative radiotherapy	Palliative radiotherapy	5–7 weeks	%1 ②③④⑤⑥⑪⑫⑬

T observation group, C control group, PC pancreatic cancer; Outcome indicators: ①CR, complete remission; ②PR, partial remission; ③SD, stabilize; ④PD, progress; ⑤ ORR objective response rate, ⑥ DCR disease control rate, ⑦ OS overall survival, ⑧ PFS progression-free survival, ⑨ 1-year survival rate, ⑩2-year survival rate, ⑪ leucopenia, ⑫ thrombocytopenia, ⑬ nausea and vomiting, ⑭ albuminuria, ⑮ radiation-induced inflammation, ⑯ liver and kidney damage, ⑰ hypertension。SBRT stereotactic body radiotherapy, IMRT intensity modulated radiation therapy,3DCRT three-dimensional conformal radiation therapy

ISSN: 1477-7819